Literature DB >> 17109738

Announcing a TAFIa mutant with a 180-fold increased half-life and concomitantly a strongly increased antifibrinolytic potential.

E Ceresa, M Peeters, P J Declerck, A Gils.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 17109738     DOI： 10.1111/j.1538-7836.2007.02322.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  3 in total

Review 1.  Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

Authors:  J L Willemse; E Heylen; M E Nesheim; D F Hendriks
Journal:  J Thromb Haemost       Date:  2009-08-28       Impact factor: 5.824

Review 2.  Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

3.  Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.

Authors:  Zainab A Bazzi; Danielle Lanoue; Mouhanned El-Youssef; Rocco Romagnuolo; Janice Tubman; Dora Cavallo-Medved; Lisa A Porter; Michael B Boffa
Journal:  BMC Cancer       Date:  2016-05-24       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.